Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.9 (78 reviews) Sold : Login>>
Novo Nordisk advances obesity candidate to late-stage program after weight loss of less than 12% US$ 23.78 Min. order: 1 piece ★★★★★ 4.1 (155 reviews) Sold : Login>>
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide US$ 22.60 Min. order: 1 piece ★★★★★ 4.0 (127 reviews) Sold : Login>>
Taking The BPC-157 & TB-500 WOLVERINE STACK | Thomas Delauer US$ 22.11 Min. order: 1 piece ★★★★★ 5.0 (86 reviews) Sold : Login>>
Development of Cagrilintide, a Long-Acting Amylin Analogue US$ 28.84 Min. order: 1 piece ★★★★★ 5.0 (77 reviews) Sold : Login>>